Bovini Asia 1/O type foot-and-mouth disease bivalent multi-epitope vaccine and preparation method and application thereof
A multi-epitope, foot-and-mouth disease virus technology, applied in chemical instruments and methods, DNA/RNA fragments, pharmaceutical formulations, etc., can solve problems such as inability to provide cross-immune protection, and achieve reduced immunization costs, maintaining immunogenicity, and comprehensive protection Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0037] Example 1 Preparation of bovine Asia1 / O type foot-and-mouth disease virus composite multi-epitope recombinant antigen (Asia1 / O / BCIgG)
[0038] 1. Bioinformatics analysis of O-type foot-and-mouth disease virus VP1 gene:
[0039] The structural protein VP1 of foot-and-mouth disease virus is the dominant antigen of the virus. Whether it is the isolated and purified natural VP1 protein or the recombinant expression product, it can induce the body to produce protective neutralizing antibodies, which is type-specific. In this study, DNAStar biological software was used to analyze the sequence of the representative strain O / China / 99 (GenBank accession number: AF506822) of bovine O-type foot-and-mouth disease virus isolated in my country, and the dominant antigenic epitope was determined to be 140-160 amino acids and 200-213 amino acids For another B antigen epitope. At the same time, 21-40 amino acids of VP1 protein region and 20-34 amino acids of VP4 were selected as T cell e...
Embodiment 2
[0053] Example 2 Preparation of bovine Asia1 / O type foot-and-mouth disease bivalent multi-epitope vaccine and immune efficacy experiment
[0054] 1. Vaccine preparation:
[0055] The purified protein Asia1 / O / BCIgG obtained in Example 1 was quantified by the Bio-Rad quantitative kit and then diluted to 1 mg / ml, either alone or with the purified full-length 3D protein (shown in SEQ ID NO: 10) and recombinant antigen by 1 : 2 (concentration ratio) after preparation, add an equal volume of oil adjuvant ISA206 (France) to emulsify into a vaccine preparation.
[0056] 2. Guinea pig immune efficacy test:
[0057] With the prepared vaccine, 0.5ml of each guinea pig was inoculated by intramuscular route (50μg antigen or 50μg antigen + 25μg 3D protein) to immunize 5 guinea pigs respectively. The results of the immunization experiment showed that after 28 days of the first immunization, whether it was Asia1 / O / BCIgG recombinant Guinea pigs immunized with antigen alone or combined with 3...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com